Insider sale details
Director Barry J. Simon of ImmunityBio, Inc. (NASDAQ: IBRX) executed sales totaling 175,000 shares of common stock across two trading dates - February 20 and February 23, 2026. The trades generated approximately $1.78 million in proceeds, with execution prices spanning from $9.25 to $10.2491 per share. The transactions were disclosed in a Form 4 filing with the Securities and Exchange Commission and were implemented under a Rule 10b5-1 trading arrangement that Simon adopted on September 4, 2024.
Related equity activity
On February 22, Simon converted 15,243 Restricted Stock Units (RSUs) into common shares at an exercise price of $0. That same day he disposed of 6,026 of those shares to satisfy tax withholding obligations; those shares were valued at $8.70 each, equating to $52,426.
After accounting for these movements, Simon holds 2,925,821 shares of ImmunityBio directly.
Market context and valuation note
The insider sales come as ImmunityBio’s shares trade above the company’s 52-week high. The stock was reported at $11.54, compared with a 52-week high of $11, and has delivered a substantial run-up of 396% year-to-date and 337% over the past six months. Analysis from InvestingPro cited in the company filing indicates that the stock appears overvalued at current levels and points interested investors toward additional ProTips and financial metrics available through that service.
Commercial performance and partnerships
ImmunityBio has recently reported significant commercial progress for ANKTIVA, its cancer treatment. Full-year revenue for ANKTIVA reached $113 million in 2025, representing a 700% increase compared with the prior year. The company also posted fourth-quarter net product revenue of $38.3 million, a 20% increase from the third quarter and a 431% rise year-over-year.
To broaden ANKTIVA’s market footprint, ImmunityBio entered into a commercialization agreement with Accord Healthcare covering 30 European countries. The plan calls for the deployment of an 85-person sales force to support commercialization efforts in those markets. This expansion follows conditional marketing authorization from the European Commission, which permits ANKTIVA’s use for certain types of bladder cancer across 33 countries.
Separately, ImmunityBio established distribution arrangements with Biopharma and Cigalah Healthcare to supply ANKTIVA in Saudi Arabia and the wider Middle East and North Africa region. The company has obtained the necessary approvals from the Saudi Food and Drug Authority and expects ANKTIVA to be available in the country within 60 days.
Analyst reaction
Responding to these developments, H.C. Wainwright raised its price target on ImmunityBio to $15 and maintained a Buy rating on the shares.
Readers should note that the filing, company disclosures, and the valuation commentary cited above constitute the factual record referenced in this report.